Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
Mária Krchniaková, J. Škoda, Jakub Neradil, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3157-3157
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 388
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 115
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 73
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Alison Kurimchak, Carlos Herrera-Montávez, Sara Montserrat‐Sangrà, et al.
Science Signaling (2022) Vol. 15, Iss. 749
Open Access | Times Cited: 63
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 14
Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters
Somayeh Nazari, Fatemeh Mosaffa, Alireza Poustforoosh, et al.
Toxicology and Applied Pharmacology (2024) Vol. 484, pp. 116866-116866
Closed Access | Times Cited: 8
The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors
Jason Goebel, Jean Chmielewski, Christine A. Hrycyna
Cancer Drug Resistance (2021)
Open Access | Times Cited: 51
Tumour Microenvironment Stress Promotes the Development of Drug Resistance
Nicole A. Seebacher, Mária Krchniaková, Alexandra E. Stacy, et al.
Antioxidants (2021) Vol. 10, Iss. 11, pp. 1801-1801
Open Access | Times Cited: 50
Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
Harpinder Kaur Brar, Jiney Jose, Zimei Wu, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 59-59
Open Access | Times Cited: 31
Evaluation of the FDA-approved kinase inhibitors to uncover the potential repurposing candidates targeting ABC transporters in multidrug-resistant cancer cells: an in silico approach
Alireza Poustforoosh, Fatemeh Moosavi
Journal of Biomolecular Structure and Dynamics (2023), pp. 1-13
Closed Access | Times Cited: 20
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
Sergei Boichuk, Pavel Dunaev, И Г Мустафин, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 601-601
Open Access | Times Cited: 27
Nanomedicines for combating multidrug resistance of cancer
Ya‐Xuan Zhu, Hao‐Ran Jia, Qiu‐Yi Duan, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2021) Vol. 13, Iss. 5
Closed Access | Times Cited: 29
Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116845-116845
Closed Access
c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter
Somayeh Nazari, Fatemeh Mosaffa, Alireza Poustforoosh, et al.
Journal of Pharmacy and Pharmacology (2025)
Closed Access
Spiroindoline quinazolinedione derivatives as inhibitors of P-glycoprotein: potential agents for overcoming multidrug resistance in cancer therapy
Fatemeh Moosavi, Masoumeh Divar, Soghra Khabnadideh, et al.
Molecular Diversity (2025)
Closed Access
PAC-1 Synergizes with Sunitinib to Enhance Cell Death in Pancreatic Neuroendocrine Tumors
Hyang Yeon Lee, Myung‐Ryul Lee, Timothy M. Fan, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 1140-1151
Closed Access
Tyrosine kinase inhibitors in Ewing’s sarcoma: a systematic review
Ahmad Assi, Mohamad Farhat, Rami Mohanna, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
Yohei Sekino, Jun Teishima, Gangning Liang, et al.
International Journal of Urology (2022) Vol. 29, Iss. 12, pp. 1419-1428
Open Access | Times Cited: 16
Local Anesthetic Ropivacaine Exhibits Therapeutic Effects in Cancers
Peng Xu, Shao-bo Zhang, Lili Tan, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
Imke H. Bartelink, Eveline Annette van de Stadt, Anke F. Leeuwerik, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 796-796
Open Access | Times Cited: 15
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
Serena Astore, Giulia Baciarello, Linda Cerbone, et al.
Cancer Drug Resistance (2023), pp. 517-46
Open Access | Times Cited: 8
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
Seongjae Kim, Jung Min Park, Soeun Park, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 8
Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients
Eveline Annette van de Stadt, Maqsood Yaqub, Robert C. Schuit, et al.
Diagnostics (2022) Vol. 12, Iss. 4, pp. 883-883
Open Access | Times Cited: 12
Cancer-Type Organic Anion Transporting Polypeptide 1B3 Is Localized in Lysosomes and Mediates Resistance against Kinase Inhibitors
Bastian Haberkorn, Stefan Oswald, Niklas Kehl, et al.
Molecular Pharmacology (2022) Vol. 102, Iss. 6, pp. 248-258
Open Access | Times Cited: 10
Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery
Sukanta Satapathy, Chandra Sekhar Patro
Advanced Pharmaceutical Bulletin (2021)
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top